PolyPid (NASDAQ:PYPD) Issues Quarterly Earnings Results

PolyPid (NASDAQ:PYPD) issued its earnings results on Wednesday. The company reported ($1.13) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.90) by ($0.23), Zacks reports.

PolyPid Price Performance

NASDAQ:PYPD traded up $0.13 during trading hours on Thursday, reaching $3.01. 10,471 shares of the company traded hands, compared to its average volume of 26,345. The company has a debt-to-equity ratio of 1.17, a current ratio of 1.00 and a quick ratio of 1.00. The firm’s 50-day moving average is $3.02 and its 200-day moving average is $3.32. The stock has a market cap of $30.62 million, a P/E ratio of -0.38 and a beta of 1.32. PolyPid has a 1-year low of $2.37 and a 1-year high of $7.00.

Analyst Upgrades and Downgrades

PYPD has been the topic of a number of research reports. RODMAN&RENSHAW upgraded PolyPid to a “strong-buy” rating in a report on Tuesday, January 28th. HC Wainwright lowered their target price on PolyPid from $14.00 to $11.00 and set a “buy” rating on the stock in a report on Thursday, December 26th. Rodman & Renshaw assumed coverage on PolyPid in a research report on Tuesday, January 28th. They issued a “buy” rating and a $13.00 price target for the company. Finally, Craig Hallum began coverage on shares of PolyPid in a research report on Monday, November 4th. They issued a “buy” rating and a $10.00 price objective on the stock.

About PolyPid

PolyPid Ltd., a clinical-stage biopharmaceutical company, developing targeted, locally administered, and prolonged-release therapeutics using its proprietary polymer-lipid encapsulation matrix (PLEX) technology to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in a pivotal Phase 3 confirmatory trial for prevention of surgical site infections (SSIs) in patients undergoing abdominal colorectal surgery with large incisions.